ICON Healthcare Fund
Portfolio of Investments (Unaudited)
6/30/2020
| Shares | Value | |||||||
| Common Stock (100.13%) | ||||||||
| Consumer, Non-Cyclical (91.62%) | ||||||||
| Abbott Laboratories | 15,000 | 1,371,450 | ||||||
| AbbVie Inc | 39,265 | 3,855,038 | ||||||
| Alexion Pharmaceuticals Inc* | 12,281 | 1,378,419 | ||||||
| Anthem Inc | 9,100 | 2,393,118 | ||||||
| AstraZeneca PLC | 26,700 | 1,412,163 | ||||||
| Bristol-Myers Squibb Co | 59,393 | 3,492,308 | ||||||
| Cigna Corp | 16,278 | 3,054,567 | ||||||
| Edwards Lifesciences Corp* | 8,300 | 573,613 | ||||||
| Eli Lilly and Co | 31,600 | 5,188,088 | ||||||
| Global Payments Inc | 12,000 | 2,035,440 | ||||||
| HealthEquity Inc* | 14,700 | 862,449 | ||||||
| Henry Schein Inc* | 19,200 | 1,121,088 | ||||||
| Humana Inc | 5,500 | 2,132,625 | ||||||
| IQVIA Holdings Inc* | 10,538 | 1,495,131 | ||||||
| Jazz Pharmaceuticals PLC* | 9,262 | 1,021,969 | ||||||
| McKesson Corp | 13,100 | 2,009,802 | ||||||
| PRA Health Sciences Inc* | 15,100 | 1,469,079 | ||||||
| Regeneron Pharmaceuticals Inc* | 4,400 | 2,744,060 | ||||||
| Teleflex Inc | 3,000 | 1,091,940 | ||||||
| Thermo Fisher Scientific Inc | 9,882 | 3,580,644 | ||||||
| UnitedHealth Group Inc | 19,300 | 5,692,535 | ||||||
| Zoetis Inc | 24,388 | 3,342,132 | ||||||
| Total Consumer, Non-Cyclical | 51,317,658 | |||||||
| Financial (2.85%) | ||||||||
| Mastercard Inc | 5,400 | 1,596,780 | ||||||
| Industrial (4.34%) | ||||||||
| PerkinElmer Inc | 24,800 | 2,432,632 | ||||||
| Technology (1.32%) | ||||||||
| Adobe Inc* | 1,700 | 740,027 | ||||||
| Total Common Stock (Cost $44,061,501) | 56,087,097 | |||||||
| Total Investments (Cost $44,061,501) (100.13%) | 56,087,097 | |||||||
| Liabilities in Excess of Other Assets (-0.13%) | (73,838 | ) | ||||||
| Net Assets (100.00%) | 56,013,259 | |||||||
| * | Non-income producing security. |
